Johnson & Johnson (JNJ) and AbelZeta Pharma’s Anti-CD19/CD20 CAR T Therapies Show Strong Early & Long-Term Efficacy in Lymphoma

MILAN – June 16, 2025 – New clinical data from two studies presented at the European Hematology Association (EHA) 2025 Congress highlight the promising potential of dual-targeting anti-CD19/CD20 CAR T-cell therapies for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). These therapies, from Johnson & Johnson (JNJ) and AbelZeta Pharma, aim to improve upon existing single-antigen CAR T treatments.

Johnson & Johnson’s JNJ-90014496 (JNJ-4496), an investigational dual-targeting CAR T, showed encouraging early results in a Phase 1b study. For patients with one prior line of therapy (n=10), the objective response rate (ORR) was 100% and complete response rate (CRR) was 80%. In patients with two or more prior lines (n=12), ORR was 92% and CRR was 75%. Safety data was favorable, with no Grade 3/4 cytokine release syndrome (CRS) observed.

Separately, AbelZeta Pharma’s C-CAR039 (Prizloncabtagene Autoleucel), the same therapy studied in Greater China, presented impressive four-year clinical outcomes. For all R/R B-NHL patients (n=48), ORR was 91.5% and CR was 85.1%. Critically, with a median follow-up of 45.5 months, the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached, indicating highly durable responses. C-CAR039 also maintained an excellent safety profile over longer follow-up. These robust data underscore the potential of this dual-targeting CAR T approach to provide deeper, more durable remissions for patients with R/R LBCL, addressing a significant unmet medical need.